title: Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells.
abstract: Striking antigenic changes were elicited by interleukin 4 (IL-4) in the Farage human B-cell lymphoma line. After 2 days of incubation with IL-4 the expression of CD23, CD54 (ICAM-1), CD58 (LFA-3) was increased while the levels of CD21, CD22, CD38 were diminished. Prolonged incubation of Farage cells with IL-4 for 6-8 days led to increased expression of CD11a (LFA-1) CD39, CD40, and to disappearance of CD21 and CD38. The modulation of antigenic properties of Farage cells was associated with enhancement of their homotypic adhesiveness and the formation of giant clumps of cells. The recovery of Farage cells which had been exposed to IL-4 for six days was not complete and eleven days after withdrawal of the cytokine, these cells still displayed a lower level of CD21 and of CD38 than control cells. Cycling and non-cycling cells did not appear to differ in their antigenic properties, indicating that modification of the antigenic profile did not result from cell selection or cell arrest. These results showed that the pleiotropic effect of IL-4 on various cell surface structures on malignant human B cells proceeds at different rates suggesting that distinct metabolic pathways may regulate their expression.
authors.affiliation: Hubert H. Humphrey Center for Experimental Medicine and Cancer Research, Paul Ehrlich Center for the Study of WBC, Hebrew University-Hadassah Medical School, Jerusalem, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Shubinsky
authors.forename: M
authors.initials: M
authors.lastname: Schlesinger
mesh_terms: D000951:Antigens, Neoplasm / Q000378:metabolism* / Q000502:physiology; D000954:Antigens, Surface / Q000378:metabolism* / Q000502:physiology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000378:metabolism*; D002448:Cell Adhesion / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology; D006801:Humans; D015847:Interleukin-4 / Q000235:genetics / Q000493:pharmacokinetics* / Q000494:pharmacology*; D007700:Kinetics; D016393:Lymphoma, B-Cell / Q000378:metabolism* / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism* / Q000473:pathology*; D010641:Phenotype; D013499:Surface Properties / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015847:Interleukin-4